$APM News

Last published 3mo ago

3mo agoAPMAptorum Group Provides Update on DiamiR Biosciences MergerGlobeNewswirePost-Merger company, Niki BioSolutions, Inc., to Trade on Nasdaq Under Ticker "NIKI" Aptorum Group Announces 1-for-10 Reverse Share Split and Delaware Redomestication in Connection with the Merger The Merger
4mo agoAPMAptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International ConferenceGlobeNewswireNEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, July 08, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated
4mo agoAPMAptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer’s Disease BiomarkersGlobeNewswireNEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company
5mo agoAPMAptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR BiosciencesGlobeNewswireNEW YORK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company dedicated to addressing unmet medical needs, today
8mo agoAPMAptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of PennsylvaniaGlobeNewswireNEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to
8mo agoAPMAptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyGlobeNewswireHong Kong, March 06, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated March 5,
9mo agoAPMAptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's DiseaseGlobeNewswireNEW YORK, NY; NEW HAVEN, CT; PRINCETON, NJ, and TAIPEI, TAIWAN, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company
11mo agoAPMDiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 ConferenceGlobeNewswireNEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and
1y agoAPMAptorum Group Limited Announces Up To $6 Million Registered Direct OfferingGlobeNewswire$2 million upfront with up to additional $4 million of potential aggregate gross proceeds upon the exercise in full of warrants NEW YORK, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM)
1y agoAPMAs part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executivesGlobeNewswireNEW YORK, NY, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announces
1y agoAPMAptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireNEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to
1y agoAPMDiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping TestGlobeNewswireNEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and
1y agoAPMAptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price RequirementGlobeNewswireNEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group," "Aptorum" or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet
1y agoAPMAptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger AgreementGlobeNewswireNEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group," "Aptorum" or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet
1y agoAPMAptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyGlobeNewswireHong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April
1y agoAPMAptorum Group Limited Announces Pricing of $3.0 Million Registered Direct OfferingGlobeNewswireNEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in
1y agoAPMAptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024Business WireAptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided
2y agoAPMAptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business UpdateBusiness WireAptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced
2y agoAPMAptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy BusinessBusiness WireAptorum Group Limited (NASDAQ:APM), a clinical stage biopharmaceutical company ("Aptorum"), and privately-held YOOV Group Holding Ltd. ("YOOV") jointly announced today that they entered into an Agreement and Plan of
2y agoAPMAptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023Business WireAptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided
2y agoAPMAptorum Group Limited Announces Results of 2023 Annual General Meeting of ShareholdersBusiness WireAptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced
2y agoAPMAptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023Business WireAptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today
3y agoAPMAptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for NeuroblastomaBusiness WireAptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has
3y agoAPM PARIS:APMAptorum Group Limited Announces Voluntary Delisting from Euronext ParisBusiness WireRegulatory News: Aptorum Group Limited (the "Company") (NASDAQ:APM, PARIS:APM) announced today that following a comprehensive review of the trading volume, costs and administrative requirements related to its listing
3y agoAPM PARIS:APMAptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity DeficiencyBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and
3y agoAPM PARIS:APMAptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations LimitedBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Company"), today announced that its wholly owned subsidiary Aptorum Therapeutics Limited ("ATL") has entered into a non-binding
3y agoAPM PARIS:APMAptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business UpdateBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and
3y agoAPM PARIS:APMAptorum Group Enters into Letter of Intent and Term Sheet To Acquire U GroupBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Company"), today announced that it entered into a non-binding Letter of Intent and Term Sheet ("Term Sheet") for the acquisition
3y agoAPM PARIS:APMAptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting NeuroblastomaBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announces the completion of an end of Phase 1 (EOP1) meeting with the US Food
3y agoAPM PARIS:APMAptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus AureusBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions with the US Food and Drug
3y agoAPM PARIS:APMAptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in ChinaBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group"), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to tackling unmet medical needs, announces
3y agoAPM PARIS:APMAptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares DeficiencyBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and
3y agoAPM PARIS:APMAptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023Business WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and
3y agoAPM PARIS:APMAptorum Group Announces 1-for-10 Reverse Stock SplitBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) (the "Company") a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune and infectious diseases, today
3y agoAPM PARIS:APMAptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina PlatformsBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune and infectious diseases, is pleased to
3y agoAPM PARIS:APMAptorum Group Limited Announces Results of 2022 Annual General Meeting of ShareholdersBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and
3y agoAPM PARIS:APMAptorum Group Announces Completion of $3 Million Convertible Note due 2023Business WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and
3y agoAPM PARIS:APMAptorum Group Announces Offering of $3 Million Convertible Note due 2023Business WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and
3y agoAPM PARIS:APMAptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)Business WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune diseases and infectious diseases, is pleased
3y agoAPM PARIS:APMAptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price DeficiencyBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and
4y agoAPM PARIS:APMAptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022Business WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and
4y agoAPM PARIS:APMAptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022Business WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a b
4y agoAPM PARIS:APMAptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)ACCESS NewswireORLANDO, FL / ACCESSWIRE / September 23, 2022 / RedChip Companies will air an interview on Aptorum Group Limited (NASDAQ:APM)(PARIS:APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases
4y agoAPM PARIS:APMAptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong KongBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group"), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to tackling unmet medical needs, announces the commercial launch of NativusW
4y agoAPM PARIS:APMAptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular DiagnosticsBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune diseases and infectious diseases, is pleased to announce further updates on th
4y agoAKAN APM BWV GNS+6Notice to Boustead Securities Customers Who Purchased IPOsGlobeNewswireNEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- The securities law firm of KlaymanToskes is interested in speaking with current and former customers of Boustead Securities that participated in IPOs offered through the company. Boustead offered IPOs that ha
4y agoAPM PARIS:APMAptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022Business WireAptorum Group Limited (NASDAQ:APM, PARIS:APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren Lui, CEO and Executive Director o
4y agoAPM PARIS:APMAptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)ACCESS NewswireNEW YORK, NY and LONDON, UK, and PARIS, FRANCE / ACCESSWIRE / August 19, 2022 / RedChip Companies will air an interview on Aptorum Group Limited (NASDAQ:APM, PARIS:APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs i
4y agoAPM PARIS:APMAptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022Business WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren Lui, Presiden
4y agoAPM PARIS:APMAptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastomaBusiness WireRegulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, is pleased to announce the finalized data from the Phase 1 clinical trial of SACT-1, a repurposed small molecul